Quoin publishes case report showing 21‑month clear skin in pediatric Netherton Syndrome patient
Quoin Pharmaceuticals announced that a peer‑reviewed paper describing a compassionate‑use case of its investigational lotion QRX003 was published online on October 13, 2026. The report details a pediatric Netherton‑Syndrome patient whose skin cleared and itch disappeared after 21 months of daily whole‑body application, with no treatment‑related adverse events. Quoin said it expects to finish enrollment for its Phase 2/3 study by the end of 2026 and to release topline results in the second quarter of 2027.
Why it matters
The company’s forward‑looking statement indicates that data from the late‑stage trial will become available in Q2 2027, which could materially affect the valuation of QNRX when released. Completion of enrollment by year‑end also removes execution risk for the study timeline.
Key facts
- 1The peer‑reviewed manuscript was published online on October 13, 2026. stocktitan.net
- 2After six weeks of QRX003 treatment the patient’s Investigator’s Global Assessment improved from 4 (severe) to 1 (almost clear). stocktitan.net
- 3By eight months the IGA was 0 (clear) and the Worst Itch Numeric Rating Scale fell from 5 to 0. stocktitan.net
- 4The patient remained at IGA 0 for most of the 21‑month period, with occasional IGA 1 readings. stocktitan.net
- 5No treatment‑related adverse events were reported during the 21‑month exposure. stocktitan.net
- 6Full recruitment for the ongoing Phase 2/3 Netherton‑Syndrome study is expected to be completed by the end of 2026, with topline data anticipated in Q2 2027. stocktitan.net
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.